Who actually benefits from proton and carbon-ion therapy — and who does not need to pay for it

The physical advantage of proton and carbon-ion therapy is concentrating dose in the target while sparing surrounding normal tissue. That matters most when the tumour sits next to a critical organ, or in children whose developing tissue must be protected; it matters much less when the tumour is already radiosensitive and no critical structure is nearby.

Situations where the benefit is usually clear

• Nasopharyngeal and skull-base tumours: target adjacent to brainstem, optic nerves and temporal lobe, reducing late neurological injury and second-tumour risk;
• Localised prostate cancer: dose escalation with lower late rectal and bladder toxicity;
• Paediatric and adolescent solid tumours: less impact on growing bone, endocrine function and cognition;
• Spine, mediastinal and retroperitoneal tumours: adjacent to cord or great vessels, where conventional doses are limited.

Common misconceptions

• Misconception one: that protons are more effective for everyone with advanced disease. Once metastases are widespread, local dose intensity is no longer the main driver of survival.
• Misconception two: that it replaces surgery. Most solid tumours still need surgery-led combined treatment, with radiotherapy as one component.
• Misconception three: confusing “can be done” with “should be done”. Indication is decided jointly by radiation oncology and surgery, not by the patient alone.

Published outcomes and cost reference

Shanghai Proton and Heavy Ion Center publishes more than 10,000 patients treated with an overall five-year survival of 70.4%; primary nasopharyngeal cancer at 93.8% and localised prostate cancer at 97.2%. The average course costs about RMB 310,000 and lasts four to six weeks. These are population figures from that centre; individual prognosis must be assessed by stage and pathology.